vs
Side-by-side financial comparison of Invivyd, Inc. (IVVD) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $11.5M, roughly 1.5× TRANSACT TECHNOLOGIES INC). On growth, Invivyd, Inc. posted the faster year-over-year revenue change (24.5% vs 11.9%).
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
IVVD vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.2M | $11.5M |
| Net Profit | $-11.1M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -73.0% | -10.1% |
| Net Margin | -64.3% | — |
| Revenue YoY | 24.5% | 11.9% |
| Net Profit YoY | 40.0% | — |
| EPS (diluted) | $0.02 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.2M | $11.5M | ||
| Q3 25 | $13.1M | $13.2M | ||
| Q2 25 | $11.8M | $13.8M | ||
| Q1 25 | $11.3M | $13.1M | ||
| Q4 24 | $13.8M | $10.2M | ||
| Q3 24 | $9.3M | $10.9M | ||
| Q2 24 | $2.3M | $11.6M | ||
| Q1 24 | $0 | $10.7M |
| Q4 25 | $-11.1M | — | ||
| Q3 25 | $-10.5M | $15.0K | ||
| Q2 25 | $-14.7M | $-143.0K | ||
| Q1 25 | $-16.3M | $19.0K | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $-60.7M | $-551.0K | ||
| Q2 24 | $-47.2M | $-319.0K | ||
| Q1 24 | $-43.5M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | -73.0% | -10.1% | ||
| Q3 25 | -84.0% | 0.1% | ||
| Q2 25 | -127.8% | -1.9% | ||
| Q1 25 | -149.7% | -0.1% | ||
| Q4 24 | -139.1% | -10.3% | ||
| Q3 24 | -670.0% | -7.7% | ||
| Q2 24 | -2175.2% | -3.8% | ||
| Q1 24 | — | -12.2% |
| Q4 25 | -64.3% | — | ||
| Q3 25 | -79.7% | 0.1% | ||
| Q2 25 | -124.4% | -1.0% | ||
| Q1 25 | -144.1% | 0.1% | ||
| Q4 24 | -133.5% | — | ||
| Q3 24 | -653.1% | -5.1% | ||
| Q2 24 | -2086.9% | -2.8% | ||
| Q1 24 | — | -9.7% |
| Q4 25 | $0.02 | $-0.11 | ||
| Q3 25 | $-0.06 | $0.00 | ||
| Q2 25 | $-0.12 | $-0.01 | ||
| Q1 25 | $-0.14 | $0.00 | ||
| Q4 24 | $-0.14 | $-0.80 | ||
| Q3 24 | $-0.51 | $-0.06 | ||
| Q2 24 | $-0.40 | $-0.03 | ||
| Q1 24 | $-0.38 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.7M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $241.5M | $31.1M |
| Total Assets | $276.9M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $226.7M | $20.4M | ||
| Q3 25 | $85.0M | $20.0M | ||
| Q2 25 | $34.9M | $17.7M | ||
| Q1 25 | $48.1M | $14.2M | ||
| Q4 24 | $69.3M | $14.4M | ||
| Q3 24 | $106.9M | $11.3M | ||
| Q2 24 | $147.9M | $11.1M | ||
| Q1 24 | $189.4M | $10.6M |
| Q4 25 | $241.5M | $31.1M | ||
| Q3 25 | $93.1M | $31.8M | ||
| Q2 25 | $42.8M | $31.3M | ||
| Q1 25 | $54.1M | $30.9M | ||
| Q4 24 | $67.5M | $30.6M | ||
| Q3 24 | $83.2M | $38.4M | ||
| Q2 24 | $140.6M | $38.5M | ||
| Q1 24 | $178.5M | $38.6M |
| Q4 25 | $276.9M | $44.8M | ||
| Q3 25 | $139.2M | $45.0M | ||
| Q2 25 | $89.1M | $44.5M | ||
| Q1 25 | $103.7M | $44.2M | ||
| Q4 24 | $129.5M | $44.0M | ||
| Q3 24 | $161.9M | $50.5M | ||
| Q2 24 | $177.3M | $50.4M | ||
| Q1 24 | $215.5M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.5M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.5M | $609.0K | ||
| Q3 25 | $-8.3M | $3.6M | ||
| Q2 25 | $-13.3M | $3.6M | ||
| Q1 25 | $-21.1M | $-161.0K | ||
| Q4 24 | $-37.6M | $2.4M | ||
| Q3 24 | $-41.1M | $327.0K | ||
| Q2 24 | $-41.6M | $636.0K | ||
| Q1 24 | $-50.2M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-13.3M | $3.6M | ||
| Q1 25 | $-21.3M | $-171.0K | ||
| Q4 24 | $-37.6M | $2.4M | ||
| Q3 24 | $-41.1M | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | $-50.4M | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | -112.9% | 25.9% | ||
| Q1 25 | -188.2% | -1.3% | ||
| Q4 24 | -272.2% | 23.2% | ||
| Q3 24 | -441.6% | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.0% | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
